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Abstract 
Perianal Paget’s disease is a rare malignancy. It is rarely isolated and often associated 
with an underlying adenocarcinoma. It usually presents with anal itchiness and 
discomfort and can be misdiagnosed as hemorrhoids. Once the diagnosis of perianal 
Paget’s disease is granted, extensive work-up to find an underlying primary malignancy 
is crucial. Surgery is the standard modality of treatment of extramammary Paget’s 
disease (EMPD) with recurrence rates of 44–60%. Other different treatment modalities 
including radiotherapy, laser therapy, topical and systemic chemotherapy and the new 
emerging, promising photodynamic therapy are in the field of study. A 76-year-old man 
was referred to our hospital with a one-year history of anal itchiness and intermittent 
rectal bleeding. Skin shave and punch biopsies from the perianal area were reported 
back as perianal Paget’s disease with no underlying adenocarcinoma. The 
immunohistochemical stains were positive for cytokeratin 7 but also positive for 
cytokeratin 20 and CEA which indicated the essentiality of extensive investigations to 
find a primary malignancy. Skin exam showed no primary source. The investigations were 
unable to find the primary malignancy. Given the results of immunohistochemical stains 
we recommended local perianal Paget’s disease resection. The intraoperative frozen 
section showed adenocarcinoma around the anal sphincter. Ten days later the patient 
underwent an abdominoperineal resection and the final pathology report showed 
extensive adenocarcinoma in three quadrants of the perianal area with focal 
involvement of the rectal mucosa. We recommended an adjuvant chemotherapy with 
FOLFOX following surgery given the bulkiness of the disease. We conclude that once 
perianal Paget’s disease is diagnosed, an extensive work-up should be done to find the 
underlying primary malignancy. Immunohistochemical stains are helpful in raising the 
suspicion of underlying primary malignancy. Finding an underlying primary malignancy 
in patients with EMPD is prompt to choose the treatment modality and estimate the 
prognosis. 
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A malignant change of the areola skin in association with underlying breast carcinoma 
was first reported by Sir James Paget in 1874 [1]. However, perianal extramammary 
Paget’s disease (EMPD) was first described in 1893 [2]. It affects individuals between the 
ages of 50 and 80 years and is more common in women and white-skinned races [3]. 
EMPD is a usually noninvasive adenocarcinoma of the skin outside of the mammary 
gland and the most frequently affected site is the vulva, followed by perineal, perianal, 
scrotal and penile skin. Less commonly, the axilla, buttocks, thighs, eyelids and external 
auditory canal may be affected [4]. The origin of the neoplastic cells could be apocrine 
glands or epithelial stem cells. Skin areas rich in apocrine glands such as the genital region 
are typical sites of EMPD.  
The signs and symptoms are a skin lesion often mistaken as an eczema that may be 
itchy or painful. A biopsy will establish the diagnosis. The histology of the lesion is the 
same as for Paget’s disease of the breast. The disease is rare and only fewer than 300 cases 
have been reported in the literature [5]. The rate of malignancy associated with perianal 
Paget’s disease ranges from 33 to 86% [6]. The majority are colorectal and tubo-ovarian 
cancers. If present, an underlying invasive carcinoma carries a poor prognosis [7–9]. 
Therefore search for an underlying primary is essential before any treatment [10].  
The treatment of perianal Paget’s disease is essentially surgical. Wide local excision is 
the preferred approach for noninvasive, locally confined disease [11–15]. When the 
disease is associated with an underlying carcinoma of the anus or rectum, the procedure 
of choice is an abdominoperineal resection with wide excision of the cutaneous lesion [5]. 
The recurrence rates after surgery range between 44 and 60% [3, 6, 7, 16] and thus 
prompt other treatment modalities including radiotherapy, laser therapy, topical and 
systemic chemotherapy and the new emerging, promising photodynamic therapy to be in 
the field of study. 
Case Report 
A 76-year-old man was referred to our hospital with a one-year history of perianal irritation and 
intermittent rectal bleeding. The patient had neither weight loss nor further gastrointestinal symptoms. 
He had no family history of colon cancer or Paget’s disease, but his mother had a history of malignant 
skin melanoma. The physical exam was unremarkable with no suspicious skin lesions but small external 
hemorrhoids which were not tender. There was no lymphadenopathy appreciated. The patient received 
treatment with topical cortisone cream without improvement. A sigmoidoscopy was done and came 
back negative. The external hemorrhoids were cauterized. Nevertheless the patient continued to 
complain of the perianal irritation so local steroid injections were given with minimal relief. 
A perianal shaved biopsy was done and the pathology report came back as perianal EMPD. Properly 
controlled immunohistochemical stains were positive for cytokeratin 7 (a sensitive marker for almost all 
pagetoid neoplasms of the breast and genital skin), also positive for cytokeratin 20 and CEA (which 
indicates the essentiality to find out underlying primary malignancy [17]) but negative for HMB-45 
(which is positive in melanoma). Mucicarmine stain was positive as well. The serum CEA marker was 
negative. A repeat punch biopsy of the perianal lesion was done and the pathology was reviewed by two 
university hospitals. It confirmed the diagnosis of perianal Paget’s disease and was negative for any 
underlying adenocarcinoma. 
A CT scan for the chest, abdomen and pelvis was negative. A colonoscopy was done and showed a 
large sessile polyp in the cecum, three small benign polyps in the right colon and some scattered small 
polyps in the transverse colon which were all removed and the pathology confirmed the benign process. 
Given the results of immunohistochemical stains which raised the suspicion, we recommended local 
wide excision of the perianal area containing the Paget’s disease lesion. To the surprise of the surgical 
team, the frozen section showed extensive underlying invasive moderately differentiated  
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adenocarcinoma surrounding the anal sphincter. The margins were positive for remaining 
adenocarcinoma, so ten days later the patient underwent abdominoperineal resection with 
sigmoidectomy and permanent colostomy was granted. 
The final pathology showed EMPD involving all four quadrants of the perianal area with invasive 
adenocarcinoma involving three quadrants of the perianal area. The pathology also reported extension 
of Paget’s disease into the anal gland ducts and involvement of the rectal mucosa. There was no 
evidence of angiolymphatic invasion, but the adenocarcinoma was focally invading the underlying 
muscles. Thirteen lymph nodes were removed and reported as benign. We recommended to the patient 
a course of FOLFOX-based adjuvant chemotherapy following surgery given the bulkiness of the disease 
in the pelvis and the involvement of the anal sphincter. 
Six-month follow-up showed no recurrence of Paget’s disease or adenocarcinoma. The patient had 
side effects from the chemotherapy including neutropenia which required leukine injections. He could 
not complete the seventh cycle secondary to allergic reaction to oxaliplatin including flushing, 
diaphoresis and itching with nausea, so the infusion was stopped. The reaction subsided immediately 
but the patient did not prefer to be re-challenged so the subsequent cycles were 5-fluorouracil-based 
only. The patient has good energy level with good appetite and no urinary symptoms have been 
reported so far. 
Discussion 
EMPD is a rare malignancy. Once the diagnosis of EMPD is granted, an extensive 
work-up should be done to rule out underlying primary malignancy. Suitable 
investigations may include: pelvic ultrasound scan, hysteroscopy, laparoscopy and/or an 
MRI scan of the pelvis; colonoscopy, sigmoidoscopy and/or barium enema; cystoscopy 
and IVP; mammogram and chest X-ray [18]. 
Surgery is the standard modality of treatment of EMPD with recurrence rates of 44–
60% [3, 6]. The reason behind the high recurrence rate even after extensive resection is 
the multicentric nature of EMPD which causes the intrasurgical frozen section analysis of 
the margins to be misleading [19]. Moh’s micrographic surgery has shown promise for 
reducing local recurrence rates in EMPD [20]. 
Radiation therapy is also a modality to treat EMPD. There are no randomized 
controlled trials to compare surgery with radiation therapy for EMPD. However, 
radiation therapy for EMPD may be indicated in patients medically unfit for surgery, for 
recurrence following surgery, in any patient who wishes to preserve the functional and 
structural integrity of the vulva by avoiding multiple surgeries, or as an adjuvant to 
surgery in patients with an underlying adenocarcinoma, where there is a high risk of local 
recurrence with surgery alone [21]. 
Topical chemotherapeutic agents including 5-fluorouracil (5-FU), bleomycin and 
imiquimod have been used to treat EMPD. 5-FU may be useful for symptomatic relief, 
preoperative delineation of disease extent, cytoreduction prior to surgery and 
postoperative detection of early disease recurrence [22, 23]. Bleomycin was used by 
Watring et al. to treat patients with recurrent vulval EMPD with no associated invasive 
carcinoma and achieved 57% complete remission [24]. Imiquimod was reported to 
achieve clinical and histological cure [25, 26]. Systemic chemotherapy is also used to treat 
EMPD with different combinations available. Case reports have recorded complete 
response to mitomycin C and 5-FU [27] and carboplatin and 5-FU [28]. Watanabe at al. 
reported one complete response when using a combination of mitomycin C, etoposide 
and cisplatin in three patients with partial response in the other two [29]. Systemic 
chemotherapy can be recommended if surgery and radiotherapy are contraindicated [3].   
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Photodynamic therapy is a new emerging and promising modality for treating EMPD 
since the mid-nineties [30]. This technique uses a tumor localizing photoreactive drug 
like 5-aminolevulinic acid (5-ALA) with appropriate wavelength light to destroy the 
tumor cells [31]. Shieh et al. [30] treated five patients with EMPD and were successful in 
three of five patients who achieved complete response. More recently Li et al. [32] 
reported a patient with perianal EMPD and achieved complete cure after the second 
course of photodynamic therapy. They used topical 5-ALA in the first session of 
treatment and topical 5-ALA with intravenous HiPorfin in the second session. 
Laser therapy for EMPD appears to carry a very high recurrence rate [33]. Some 
authors have used CO2 laser ablation guided by photodynamic diagnosis using 
ALA-induced fluorescence [34]. 
The functional results after repair of large perianal defects are acceptable and overall 
quality of life is similar to the normal population although a large proportion of patients 
have some form of incontinence that impacts certain aspects of their quality of life [35].  
We conclude that once perianal Paget’s disease is diagnosed, an extensive work-up 
should be done to find the underlying primary malignancy. Immunohistochemical stains 
are helpful in raising the suspicion of underlying primary malignancy especially with 
positive cytokeratin 20 and CEA [17]. Finding an underlying primary malignancy in 
patients with EMPD is prompt to choose the treatment modality and estimate the 
prognosis. If the patient has an extensive underlying primary adenocarcinoma with 
positive margins in the local wide excision, an abdominoperineal resection should be 
considered. We recommended to our patient a course of adjuvant chemotherapy with 
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